🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

247 results for “Pari Pharma GmbH” Clear

  1. SODIUM CHLORIDE, Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe.

    Pari Pharma GmbH

    PEDIATRIC ACUTE MYOCARDITIS

    phase 3 small molecule active

    1 trial

  2. SODIUM CHLORIDE, LEVETIRACETAM VIATRIS 100 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Adult ICU patients with septic shock

    phase 3 small molecule active

    1 trial

  3. SODIUM CHLORIDE, ROPIVACAINE

    Pari Pharma GmbH

    Cancer surgery

    phase 3 small molecule active

    1 trial

  4. SODIUM CHLORIDE, Truxima 500 mg concentrate for solution for infusion

    Pari Pharma GmbH

    Patient with stabilized SSc-ILD (as defined by a decline of FVC ≤ 5%) following RTX induction treatment

    phase 3 small molecule active

    1 trial

  5. Solution de chlorure de sodium à 0,9%, Allogeneic umbilical cord derived MSC (thawed and washed)

    Pari Pharma GmbH

    Adult Patients kidney transplant recipients who have developed chronic humoral rejection, diagnosed through a kidney biopsy (Banff 2017 Classification), resistant to conventional treatment (3 injections at one-month intervals of 2g/kg of IVIG)

    phase 3 small molecule active

    1 trial

  6. Sufentanil Mylan 50 microgrammes/ml solution injectable, MORPHINE HYDROCHLORIDE, CHLORURE DE SODIUM 0,9 % LAVOISIER, solution pour perfusion

    Pari Pharma GmbH

    vaso-occlusive crisis due to sickle cell disease

    phase 3 small molecule active

    1 trial

  7. TETRACOSACTIDE , BETAMETHASONE , Placebo of fludrocortisone, Placebo of hydrocortisone hemisuccinate, FLUDROCORTISONE , HYDROCORTISONE HEMISUCCINATE

    Pari Pharma GmbH

    Critically ill patients suffering from CIRCI

    phase 3 small molecule active

    1 trial

  8. TOCILIZUMAB, Placebo of Tocilizumab

    Pari Pharma GmbH

    Giant cell arteritis with Cerebro-vascular involvement

    phase 3 small molecule active

    1 trial

  9. Tamiflu 75 mg hard capsules, DOLIPRANE 1000 mg, poudre pour solution buvable en sachet-dose

    Pari Pharma GmbH

    Adult patients admitted to the ICU for management of severe influenza infection requiring orotracheal intubation for invasive mechanical ventilation

    phase 3 small molecule active

    1 trial

  10. VALACICLOVIR ARROW 500 mg, comprimé pelliculé sécable, PREVYMIS PLACEBO, VALACICLOVIR PLACEBO, PREVYMIS 240 mg film-coated tablets

    Pari Pharma GmbH

    Diseases [C] - Virus Diseases [C02]

    phase 3 small molecule active

    1 trial

  11. VISIPAQUE 320 mg d’I/mL, solution injectable, LIPIODOL ULTRA FLUIDE 480 mg/ml, solution injectable, HEPARINE CHOAY 5 000 UI/1 ml, solution injectable, XYLOCAINE 5 mg/ml SANS CONSERVATEUR, solution injectable, Optiray 300 (300 mg I/mL), solution injectable en flacon

    Pari Pharma GmbH

    Knee OsteoArthritis

    phase 3 small molecule active

    1 trial

  12. VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, AMPHOTERICINE B, LIPOSOME, FLUCONAZOLE, FLUCONAZOLE, AMPHOTERICINE B, LIPOSOME, VORICONAZOLE, ANIDULAFUNGIN, CASPOFUNGIN, MICAFUNGIN, MICAFUNGIN

    Pari Pharma GmbH

    Uncomplicated candidemia

    phase 3 small molecule active

    1 trial

  13. XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    PANCREATIC FISTULA

    phase 3 small molecule active

    1 trial

  14. XEOMIN 200 unités, poudre pour solution injectable, Placebo of Xeomin 200 U

    Pari Pharma GmbH

    Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery)

    phase 3 small molecule active

    1 trial

  15. [18F]MNI-659

    Pari Pharma GmbH

    Patients with symptomatic and pre-symptomatic Huntington's disease

    phase 3 small molecule active

    1 trial

  16. [68Ga]Ga-PentixaFor

    Pari Pharma GmbH

    Primary aldosteronism, Primary aldosteronism

    phase 3 small molecule active

    1 trial

  17. cpFT

    Pari Pharma GmbH

    Infertility

    phase 3 small molecule active

    1 trial

  18. placebo of metformine, METFORMINE VIATRIS 500 mg, comprimé dispersible

    Pari Pharma GmbH

    Myotonic dystrophy type 1 (DM1)

    phase 3 small molecule active

    1 trial

  19. -, RIVAROXABAN, RIVAROXABAN

    Pari Pharma GmbH

    newly diagnosed or relapsing deep venous thrombosis related to Behçet’s syndrome

    phase 2 small molecule active

    1 trial

  20. 11C-UCB-J, 18F-DPA-714, [11C]PiB

    Pari Pharma GmbH

    Alzeihmer disease

    phase 2 small molecule active

    1 trial

  21. A phase 2 trial assessing Ifenprodil as a ReMyelinating repurpOsed Drug in Multiple Sclerosis – MODIF-MS

    Pari Pharma GmbH

    Multiple sclerosis

    phase 2 other active

    1 trial

  22. ADALIMUMAB, USTEKINUMAB , ADALIMUMAB , USTEKINUMAB, Olumiant 4 mg film-coated tablets

    Pari Pharma GmbH

    Folliculitis decalvans

    phase 2 small molecule active

    1 trial

  23. AMGLIDIA 6 mg/mL oral suspension

    Pari Pharma GmbH

    Transient hyperglycaemia in premature infants

    phase 2 small molecule active

    1 trial

  24. AMPHOTERICIN B , VANCOMYCIN , Gentamicin_APHP

    Pari Pharma GmbH

    Healthy volunteers : Healthy adults with no history of gastrointestinal disease Patients with IBD in remission

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources